February 2, 2021, 10:47 am ·
Japanese prefecture Yokohama announced the city-council’s draft budget for 2021, which includes JPY360 million (US$3.4 million) to back up the effort to establish casino resort in the city.
Part of that amount will be spent on the city’s resort development plan. Precisely JPY83 million will go to that as well as to Yokohama’s request-for-proposal process.
As the national Japanese protocols require, the prefecture needs to partner with a private-sector company in order to establish a casino resort. Part of the budget will be spent on the right partner.
According to some, the larger part of the money will be spent on promoting the significance of the future resort for the prefecture.
GGRAsia – Yokohama budgets US$3 4mln in 2021 for casino tilt ggrasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ggrasia.com Daily Mail and Mail on Sunday newspapers.
KUALA LUMPUR (Jan 26): S&P Global Ratings expects Genting Malaysia Bhd’s (GenM) wholly-owned subsidiary Genting New York LLC to register a sharp recovery after the Covid-19 pandemic-driven shutdown as Genting New York operations are located at the heart of the metropolitan area in New York and has a low dependency on tourists for gaming revenue.
In a note yesterday, S&P Global Ratings said that like other casinos, Genting New York’s operations were closed for six months from March 2020 due to the pandemic. However, with the resumption of normal operations from September to mid-November 2020, Genting New York s business was already nearly back to pre-Covid-19 levels,” S&P Global Ratings analysts Shawn Park, Simon Wong and Christina Lim wrote in the note.
GGRAsia – Yokohama announces RFP timeline for casino bid ggrasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ggrasia.com Daily Mail and Mail on Sunday newspapers.
KUALA LUMPUR (Jan 10): Few may pay much attention to Genting Bhd s life-sciences division. However, the biotech unit could be reaping its fruits via listing, after it merges with NASDAQ-listed GX Acquisition Corp to form a special purpose acquisition company (SPAC) in an attempt to create a publicly-listed leader in allogeneic cellular therapy.
This would also represent the first major monetisation in Genting’s life-sciences division.
On Friday, Celularity signed a definitive merger agreement with GX Acquisition Corp, of which the companies are planning to take it public by the second quarter of 2021, subject to approval of both Celularity and GX’s shareholders.